A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose (MTD) and toassess the safety and tolerability of GSK1363089 administered orally (up to twelve different doses) to subjects with solid tumors
3 years
GSK Clinical Trials
Study Director
GlaxoSmithKline
United States: Food and Drug Administration
MET111647
NCT00742131
March 2005
October 2009
Name | Location |
---|